Fuso Pharmaceutical Industries,Ltd.

Tokyo Stock Exchange 4538.T

Fuso Pharmaceutical Industries,Ltd. Current Liabilities for the year ending March 31, 2024: USD 195.90 M

Fuso Pharmaceutical Industries,Ltd. Current Liabilities is USD 195.90 M for the year ending March 31, 2024, a -8.60% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

Fuso Pharmaceutical Industries,Ltd. Current Liabilities for the year ending March 31, 2023 was USD 214.32 M, a -1.08% change year over year.
Fuso Pharmaceutical Industries,Ltd. Current Liabilities for the year ending March 31, 2022 was USD 216.67 M, a -10.34% change year over year.
Fuso Pharmaceutical Industries,Ltd. Current Liabilities for the year ending March 31, 2021 was USD 241.67 M, a 1.12% change year over year.
Fuso Pharmaceutical Industries,Ltd. Current Liabilities for the year ending March 31, 2020 was USD 238.99 M, a 0.27% change year over year.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

Tokyo Stock Exchange: 4538.T

Fuso Pharmaceutical Industries,Ltd.

CEO	Mr. Mikio Toda
IPO Date	Jan. 1, 2001
Location	Japan
Headquarters	1-7-10, Doshomachi
Employees	1,370
Sector	Consumers Staples
Industries Cleaning Supplies Automotive Parts Composite Materials Hardware & Electronics Non-Alcoholic Beverages Personal Care Pharmaceuticals Plastics

Description

Fuso Pharmaceutical Industries,Ltd. manufactures and sells pharmaceutical products in Japan. The company offers ethical drugs, such as injectables and artificial kidney dialysates; and medical machinery and equipment. It also rents real estate properties. The company was founded in 1937 and is headquartered in Osaka, Japan.

Key trends

Past 5 years